Consequently, DAPA may impede the advancement of colon cancer associated with hyperinsulinemia by diminishing tumor glucose uptake and oxidation through the reversal of hyperinsulinemia, opening up an alternative mechanism for SGLT2-inhibited tumors. The gene discussed is SLC5A2; the disease is neoplasm.